Boston, MA. International law firm Nixon Peabody LLP is proud to have represented Halma plc (HLMAF) in its $153.5 million acquisition of medical device manufacturer and distributor IZI Medical Products LLC.
Halma, based in Amersham, England, is a publicly traded global group of safety equipment companies making products for hazard detection and life protection. This acquisition enables Halma to expand its healthcare sector and produce innovative medical devices that support minimally invasive diagnosis and treatment of acute conditions, primarily cancer.
IZI Medical Products’ technologies include consumable devices used in interventional radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures. Based in Owings Mills, Maryland, the company also produces core biopsy devices used in diagnosing and treating various forms of cancer.
“We are honored to be part of this transaction and assist Halma in its mission to grow a safer and healthier future,” said Daniel Belostock, a partner with Nixon Peabody’s Corporate practice, who led the firm’s deal team. “Combining forces, these companies stand to make an even bigger positive impact against the recent increase in a wide range of medical conditions.”
IZI Medical Products will continue to operate as a stand-alone company within Halma’s healthcare sector.
In addition to Belostock, the core Nixon Peabody deal team included partners Hannah Bornstein, Brian French, Jeffrey Gilbreth, Kevin Grant, Seth Levy, Alexandra Lopez-Casero, and Thomas McCord; counsels Jenny Holmes and Brian Whittaker; associates Ben Rosborough, and Tim Sharkey, and senior attorney Shelagh Michaud.
